INTRODUCTION: Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, variability in tracer types, and challenges in multimodal integration. METHODS: We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. The pipeline is implemented as a web-based platform, requiring no local computational infrastructure or specialized software knowledge. RESULTS: petBrain provides reliable and rapid biomarker quantification, with results comparable to existing pipelines for A and T2. It shows strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreement with CSF/plasma biomarkers, clinical status, and cognitive performance. DISCUSSION: petBrain represents a powerful and openly accessible platform for standardized AD biomarker analysis, facilitating applications in clinical research.

This paper describes PARADIM, a digital infrastructure designed to support research at the interface of data science and medical imaging, with a focus on Research Data Management best practices. The platform is built from open-source components and rooted in the FAIR principles through strict compliance with the DICOM standard. It addresses key needs in data curation, governance, privacy, and scalable resource management. Supporting every stage of the data science discovery cycle, the platform offers robust functionalities for user identity and access management, data de-identification, storage, annotation, as well as model training and evaluation. Rich metadata are generated all along the research lifecycle to ensure the traceability and reproducibility of results. PARADIM hosts several medical image collections and allows the automation of large-scale, computationally intensive pipelines (e.g., automatic segmentation, dose calculations, AI model evaluation). The platform fills a gap at the interface of data science and medical imaging, where digital infrastructures are key in the development, evaluation, and deployment of innovative solutions in the real world.

Traditional guidance for intracranial aneurysm (IA) management is dichotomized by rupture status. Fundamental to the management of ruptured aneurysm is the detection and treatment of SAH, along with securing the aneurysm by the safest technique. On the other hand, unruptured aneurysms first require a careful assessment of their natural history versus treatment risk, including an imaging assessment of aneurysm size, location, and morphology, along with additional evidence-based risk factors such as smoking, hypertension, and family history. Unfortunately, a large proportion of ruptured aneurysms are in the lower risk size category (<7 mm), putting a premium on discovering a more refined noninvasive biomarker to detect and stratify aneurysm instability before rupture. In this review of aneurysm work-up, we cover the gamut of established imaging modalities (eg, CT, CTA, DSA, FLAIR, 3D TOF-MRA, contrast-enhanced-MRA) as well as more novel MR techniques (MR vessel wall imaging, dynamic contrast-enhanced MRI, computational fluid dynamics). Additionally, we evaluate the current landscape of artificial intelligence software and its integration into diagnostic and risk-stratification pipelines for IAs. These advanced MR techniques, increasingly complemented with artificial intelligence models, offer a paradigm shift by evaluating factors beyond size and morphology, including vessel wall inflammation, permeability, and hemodynamics. Additionally, we provide our institution's scan parameters for many of these modalities as a reference. Ultimately, this review provides an organized, up-to-date summary of the array of available modalities/sequences for IA imaging to help build protocols focused on IA characterization.

The purpose of this study was to investigate the impact of optic nerve tortuosity (ONT), and the interaction of globe proptosis and size on retinal ganglion cell (RGC) thickness, using retinal nerve fiber layer (RNFL) thickness, across general, glaucoma, and myopic populations. This study analyzed 17,940 eyes from the UKBiobank cohort (ID 76442), including 72 glaucomatous and 2475 myopic eyes. Artificial intelligence models were developed to derive RNFL thickness corrected for ocular magnification from 3D optical coherence tomography scans and orbit features from 3D magnetic resonance images, including ONT, globe proptosis, axial length, and a novel feature: the interzygomatic line-to-posterior pole (ILPP) distance - a composite marker of globe proptosis and size. Generalized estimating equation (GEE) models evaluated associations between orbital and retinal features. RNFL thickness was positively correlated with ONT and ILPP distance (r = 0.065, P < 0.001 and r = 0.206, P < 0.001, respectively) in the general population. The same was true for glaucoma (r = 0.040, P = 0.74 and r = 0.224, P = 0.059), and for myopia (r = 0.069, P < 0.001 and r = 0.100, P < 0.001). GEE models revealed that straighter optic nerves and shorter ILPP distance were predictive of thinner RNFL in all populations. Straighter optic nerves and decreased ILPP distance could cause RNFL thinning, possibly due to greater traction forces. ILPP distance emerged as a potential biomarker of axonal health. These findings underscore the importance of orbit structures in RGC axonal health and warrant further research into orbit biomechanics.

We investigated pharmacokinetics, dosimetric patterns, and absorbed dose (AD)-effect correlations in [¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) for metastatic neuroendocrine tumors (NETs) to develop strategies for future personalized dosimetry-guided treatments. <b>Methods:</b> Patients treated with standard [¹⁷⁷Lu]Lu-DOTATATE PRRT were recruited for serial SPECT/CT imaging. Kidneys were segmented on CT using a deep learning algorithm, and tumors were segmented at each cycle using a SPECT gradient-based tool, guided by radiologist-defined contours on baseline CT/MRI. Dosimetry was performed using an automated workflow that included contour intensity-based SPECT-SPECT registration, generation of Monte Carlo dose-rate maps, and dose-rate fitting. Lesion-level response at first follow-up was evaluated using both radiologic (RECIST and modified RECIST) and [⁶⁸Ga]Ga-DOTATATE PET-based criteria. Kidney toxicity was evaluated based on the estimated glomerular filtration rate (eGFR) at 9 mo after PRRT. <b>Results:</b> Dosimetry was performed after cycle 1 in 30 patients and after all cycles in 22 of 30 patients who completed SPECT/CT imaging after each cycle. Median cumulative tumor (<i>n</i> = 78) AD was 2.2 Gy/GBq (range, 0.1-20.8 Gy/GBq), whereas median kidney AD was 0.44 Gy/GBq (range, 0.25-0.96 Gy/GBq). The tumor-to-kidney AD ratio decreased with each cycle (median, 6.4, 5.7, 4.7, and 3.9 for cycles 1-4) because of a decrease in tumor AD, while kidney AD remained relatively constant. Higher-grade (grade 2) and pancreatic NETs showed a significantly larger drop in AD with each cycle, as well as significantly lower AD and effective half-life (T_eff), than did low-grade (grade 1) and small intestinal NETs, respectively. T_eff remained relatively constant with each cycle for both tumors and kidneys. Kidney T_eff and AD were significantly higher in patients with low eGFR than in those with high eGFR. Tumor AD was not significantly associated with response measures. There was no nephrotoxicity higher than grade 2; however, a significant negative association was found in univariate analyses between eGFR at 9 mo and AD to the kidney, which improved in a multivariable model that also adjusted for baseline eGFR (cycle 1 AD, <i>P</i> = 0.020, adjusted <i>R</i> ² = 0.57; cumulative AD, <i>P</i> = 0.049, adjusted <i>R</i> ² = 0.65). The association between percentage change in eGFR and AD to the kidney was also significant in univariate analysis and after adjusting for baseline eGFR (cycle 1 AD, <i>P</i> = 0.006, adjusted <i>R</i> ² = 0.21; cumulative AD, <i>P</i> = 0.019, adjusted <i>R</i> ² = 0.21). <b>Conclusion:</b> The dosimetric behavior we report over different cycles and for different NET subgroups can be considered when optimizing PRRT to individual patients. The models we present for the relationship between eGFR and AD have potential for clinical use in predicting renal function early in the treatment course. Furthermore, reported pharmacokinetics for patient subgroups allow more appropriate selection of population parameters to be used in protocols with fewer imaging time points that facilitate more widespread adoption of dosimetry.

This study aimed to develop an automated early warning system using a large language model (LLM) to identify acute to subacute brain infarction from free-text computed tomography (CT) or magnetic resonance imaging (MRI) radiology reports. In this retrospective study, 5,573, 1,883, and 834 patients were included in the training (mean age, 67.5 ± 17.2 years; 2,831 males), validation (mean age, 61.5 ± 18.3 years; 994 males), and test (mean age, 66.5 ± 16.1 years; 488 males) datasets. An LLM (Japanese Bidirectional Encoder Representations from Transformers model) was fine-tuned to classify the CT and MRI reports into three groups (group 0, newly identified acute to subacute infarction; group 1, known acute to subacute infarction or old infarction; group 2, without infarction). The training and validation processes were repeated 15 times, and the best-performing model on the validation dataset was selected to further evaluate its performance on the test dataset. The best fine-tuned model exhibited sensitivities of 0.891, 0.905, and 0.959 for groups 0, 1, and 2, respectively, in the test dataset. The macrosensitivity (the average of sensitivity for all groups) and accuracy were 0.918 and 0.923, respectively. The model's performance in extracting newly identified acute brain infarcts was high, with an area under the receiver operating characteristic curve of 0.979 (95% confidence interval, 0.956-1.000). The average prediction time was 0.115 ± 0.037 s per patient. A fine-tuned LLM could extract newly identified acute to subacute brain infarcts based on CT or MRI findings with high performance.

Cancer continues to be a significant international health issue, which demands the invention of new methods for early detection, precise diagnoses, and personalized treatments. Artificial intelligence (AI) has rapidly become a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer care. In this review, we performed a systematic survey of the current status of AI technologies used for cancer diagnoses and therapeutic approaches. We discuss AI-facilitated imaging diagnostics using a range of modalities such as computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, and digital pathology, highlighting the growing role of deep learning in detecting early-stage cancers. We also explore applications of AI in genomics and biomarker discovery, liquid biopsies, and non-invasive diagnoses. In therapeutic interventions, AI-based clinical decision support systems, individualized treatment planning, and AI-facilitated drug discovery are transforming precision cancer therapies. The review also evaluates the effects of AI on radiation therapy, robotic surgery, and patient management, including survival predictions, remote monitoring, and AI-facilitated clinical trials. Finally, we discuss important challenges such as data privacy, interpretability, and regulatory issues, and recommend future directions that involve the use of federated learning, synthetic biology, and quantum-boosted AI. This review highlights the groundbreaking potential of AI to revolutionize cancer care by making diagnostics, treatments, and patient management more precise, efficient, and personalized.

BackgroundDifferent Natural Language Processing (NLP) techniques have demonstrated promising results for data extraction from radiological reports. Both traditional rule-based methods like regular expressions (Regex) and modern Large Language Models (LLMs) can extract structured information. However, comparison between these approaches for extraction of specific radiological data elements has not been widely conducted. MethodsWe compared accuracy and processing time between Regex and LLM-based approaches for extracting BI-RADS scores from 7,764 radiology reports (mammography, ultrasound, MRI, and biopsy). We developed a rule-based algorithm using Regex patterns and implemented an LLM-based extraction using the Rombos-LLM-V2.6-Qwen-14b model. A ground truth dataset of 199 manually classified reports was used for evaluation. ResultsThere was no statistically significant difference in the accuracy in extracting BI-RADS scores between Regex and an LLM-based method (accuracy of 89.20% for Regex versus 87.69% for the LLM-based method; p=0.56). Compared to the LLM-based method, Regex processing was more efficient, completing the task 28,120 times faster (0.06 seconds vs. 1687.20 seconds). Further analysis revealed LLMs favored common classifications (particularly BI-RADS value of 2) while Regex more frequently returned "unclear" values. We also could confirm in our sample an already known laterality bias for breast cancer (BI-RADS 6) and detected a slight laterality skew for suspected breast cancer (BI-RADS 5) as well. ConclusionFor structured, standardized data like BI-RADS, traditional NLP techniques seem to be superior, though future work should explore hybrid approaches combining Regex precision for standardized elements with LLM contextual understanding for more complex information extraction tasks.

Medical image reconstruction aims to generate high-quality images from sparsely sampled raw sensor data, which poses an ill-posed inverse problem. Traditional iterative reconstruction methods rely on prior information to empirically construct regularization terms, a process that is not trivial. While deep learning (DL)-based supervised reconstruction has made significant progress in improving image quality, it requires large-scale training data, which is difficult to obtain in medical imaging. Recently, implicit neural representation (INR) has emerged as a promising approach, offering a flexible and continuous representation of images by modeling the underlying signal as a function of spatial coordinates. This allows INR to capture fine details and complex structures more effectively than conventional discrete methods. This paper provides a comprehensive review of INR-based medical image reconstruction techniques, highlighting its growing impact on the field. The benefits of INR in both image and measurement domains are presented, and its advantages, limitations, and future research directions are discussed.&#xD.

This paper introduces an efficient sub-model ensemble framework aimed at enhancing the interpretability of medical deep learning models, thus increasing their clinical applicability. By generating uncertainty maps, this framework enables end-users to evaluate the reliability of model outputs. We developed a strategy to generate diverse models from a single well-trained checkpoint, facilitating the training of a model family. This involves producing multiple outputs from a single input, fusing them into a final output, and estimating uncertainty based on output disagreements. Implemented using U-Net and UNETR models for segmentation and synthesis tasks, this approach was tested on CT body segmentation and MR-CT synthesis datasets. It achieved a mean Dice coefficient of 0.814 in segmentation and a Mean Absolute Error of 88.17 HU in synthesis, improved from 89.43 HU by pruning. Additionally, the framework was evaluated under image corruption and data undersampling, maintaining correlation between uncertainty and error, which highlights its robustness. These results suggest that the proposed approach not only maintains the performance of well-trained models but also enhances interpretability through effective uncertainty estimation, applicable to both convolutional and transformer models in a range of imaging tasks.